Curis, Inc. (NASDAQ:CRIS) Short Interest Up 82.0% in January

Curis, Inc. (NASDAQ:CRIS) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 81,700 shares, a growth of 82.0% from the December 31st total of 44,900 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average trading volume of 118,900 shares, the days-to-cover ratio is presently 0.7 days.

Curis Price Performance

CRIS stock traded up $0.09 during midday trading on Wednesday, hitting $3.22. 33,070 shares of the stock traded hands, compared to its average volume of 224,571. The firm has a market cap of $27.27 million, a P/E ratio of -0.41 and a beta of 3.42. The stock’s fifty day simple moving average is $3.59 and its 200-day simple moving average is $4.62. Curis has a 1-year low of $2.86 and a 1-year high of $17.49.

Institutional Trading of Curis

An institutional investor recently raised its position in Curis stock. Focused Wealth Management Inc raised its stake in shares of Curis, Inc. (NASDAQ:CRIS) by 9.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 59,204 shares of the biotechnology company’s stock after purchasing an additional 5,138 shares during the period. Focused Wealth Management Inc owned 0.70% of Curis worth $181,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Curis in a research note on Tuesday, December 10th.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.